Minidril (Ethinylestradiol, Levonorgestrel)

• Minidril, a combined estrogen‑progestogen oral contraceptive, is indicated for hormonal contraception.
• Contraception: Prevents pregnancy by inhibiting ovulation and creating cervical mucus conditions unfavorable to sperm.
• Menstrual cycle regulation: Provides predictable withdrawal bleeding and helps maintain regular menstrual cycles.
• Management of menstrual‑related symptoms: Reduces dysmenorrhea and premenstrual discomfort in women using hormonal contraception.

• Ethinylestradiol and levonorgestrel act synergistically to suppress the hypothalamic‑pituitary‑gonadal axis. Ethinylestradiol binds to estrogen receptors, providing negative feedback that reduces follicle‑stimulating hormone (FSH) release, while levonorgestrel binds to progesterone receptors, inhibiting luteinizing hormone (LH) surge. The combined effect blocks follicular development and ovulation, thickens cervical mucus, and induces endometrial changes that impede fertilisation and implantation.

Minidril may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild stomach upset often occurring early in treatment.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: swelling or discomfort of the breasts.
• Spotting or breakthrough bleeding: irregular light bleeding between periods.
• Weight changes: slight increase or decrease in body weight.
• Mood changes: irritability or emotional fluctuations.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins, potentially leading to pulmonary embolism.
• Stroke: cerebrovascular accident presenting with neurological deficits.
• Myocardial infarction: heart attack due to reduced coronary blood flow.
• Severe allergic reaction: anaphylaxis with rash, swelling, and breathing difficulty.
• Hepatic adenoma: benign liver tumor observed rarely.
• Visual disturbances: sudden loss of vision or blurred sight.

• Before prescribing Minidril, clinicians should evaluate several safety considerations.
• Assess cardiovascular risk: review history of thrombosis, smoking, hypertension, and age over 35.
• Screen for liver disease: avoid use in active hepatic impairment.
• Consider migraine history: contraindicated in women with migraine with aura.
• Evaluate clotting disorders: avoid in known thrombophilia or previous clot events.
• Inform about smoking: advise cessation, especially in women over 35.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Minidril can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Potent enzyme inducers (e.g., rifampin, carbamazepine): markedly reduce hormone levels, risking contraceptive failure.
• Combined hormonal therapy for breast cancer: antagonistic effects, contraindicated.
• Anticoagulants (e.g., warfarin): may increase risk of thrombotic events when used together.

Moderate Interactions (Monitor Closely)

• Antifungal azoles (e.g., ketoconazole): can raise hormone concentrations, requiring monitoring for side effects.
• Anticonvulsants (e.g., phenytoin, phenobarbital): may lower contraceptive efficacy, consider alternative methods.
• Herbal supplements (e.g., St. John’s wort): may decrease hormone levels, advise caution.